Abramson Cancer Center at Penn Medicine: Cardiotoxicity trials

The registry lists 11 Cardiotoxicity studies with Abramson Cancer Center at Penn Medicine as lead sponsor. 1 are open to participants now and 2 have results posted.

Phase 1 2Phase 2 1No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Hypertension and Arrhythmias in CLL Patients Treated With BTK InhibitorsEnrolling by invitationNCT06211413
• Pilot Study of an NTproBNP Guided Strategy of CardioprotectionCompletedNCT04737265Phase 1/2Results posted
• Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or TrastuzumabCompletedNCT04023110Phase 1Results posted
• Effects of Immune Checkpoint Inhibitors on Coronary MicrovasculatureActive, not recruitingNCT06332131
• Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate CancerActive, not recruitingNCT05096338
• Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast CancerActive, not recruitingNCT05078190
• Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Companion StudyCompletedNCT04361240
• Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation TherapyActive, not recruitingNCT04305613
• Cardiovascular Effects of CART Cell TherapyCompletedNCT04026737
• Cardiovascular Function in Acute LeukemiaCompletedNCT03760237
• Cardiotoxicity of Radiation Therapy (CTRT)CompletedNCT02769299